Search

Your search keyword '"Mercadal-Hally, Maria"' showing total 24 results
Start Over Author "Mercadal-Hally, Maria"
24 results on '"Mercadal-Hally, Maria"'

3. Incidence, management and outcomes in hepatic artery complications after paediatric liver transplantation: protocol of the retrospective, international, multicentre HEPATIC Registry

Author

Li, Weihao, primary, van der Doef, Hubert P J, additional, Wildhaber, Barbara E, additional, Marra, Paolo, additional, Bravi, Michela, additional, Pinelli, Domenico, additional, Minetto, Julia, additional, Dip, Marcelo, additional, Sierre, Sergio, additional, de Santibañes, Martin, additional, Ardiles, Victoria, additional, Uno, Jimmy Walker, additional, Hardikar, Winita, additional, Bates, Sue, additional, Goh, Lynette, additional, Aldrian, Denise, additional, Seisenbacher, Jonathan, additional, Vogel, Georg F, additional, Neto, Joao Seda, additional, Antunes da Fonseca, Eduardo, additional, Magalhães Costa, Carolina, additional, Ferreira, Cristina T, additional, Nader, Luiza S, additional, Farina, Marco A, additional, Dajani, Khaled Z, additional, Parente, Alessandro, additional, Bigam, David L, additional, Liang, Ting-Bo, additional, Bai, Xueli, additional, Zhang, Wei, additional, Gonsorčíková, Lucie, additional, Froněk, Jiří, additional, Bohuš, Šimon, additional, Franchi-Abella, Stéphanie, additional, Gonzales, Emmanuel, additional, Guérin, Florent, additional, Junge, Norman, additional, Baumann, Ulrich, additional, Richter, Nicolas, additional, Hartleif, Steffen, additional, Sturm, Ekkehard, additional, Rajakannu, Muthukumarassamy, additional, Palaniappan, Kumar, additional, Rela, Mohamed, additional, Pawaria, Arti, additional, Rajakrishnan, Haritha, additional, Surendran, Sudhindran, additional, Kumar, Mukesh, additional, Agarwal, Shaleen, additional, Gupta, Subhash, additional, Asthana, Sonal, additional, Bandewar, Vaishnavi, additional, Raichurkar, Karthik, additional, Spada, Marco, additional, Monti, Lidia, additional, Alterio, Tommaso, additional, Yanagi, Yusuke, additional, Uchida, Hajime, additional, Komine, Ryuji, additional, Evans, Helen, additional, Carr-Boyd, Peter, additional, Duncan, David, additional, Stefanowicz, Marek, additional, Latka-Grot, Julita, additional, Kolesnik, Adam, additional, Broering, Dieter C, additional, Raptis, Dimitri A, additional, Ann H Marquez, Kris, additional, Mali, Vidyadhar, additional, Aw, Marion, additional, Beretta, Marisa, additional, Van der Schyff, Francisca, additional, Quintero-Bernabeu, Jesús, additional, Mercadal-Hally, Maria, additional, Larrarte K, Mauricio, additional, Andres, Ane M, additional, Hernandez-Oliveros, Francisco, additional, Frauca, Esteban, additional, Casswall, Thomas, additional, Jorns, Carl, additional, Delle, Martin, additional, Gupte, Girish, additional, Sharif, Khalid, additional, McGuirk, Simon, additional, Superina, Riccardo, additional, Caicedo, Juan Carlos, additional, Jaramillo, Catalina, additional, Bitterfeld, Leandra, additional, Kastenberg, Zachary, additional, Shah, Amit A, additional, Domenick, Bryanna, additional, Acord, Michael R, additional, Mazariegos, George V, additional, Soltys, Kyle, additional, DiNorcia, Joseph, additional, Antala, Swanti, additional, Florman, Sander S, additional, Buchholz, Bettina M, additional, Herden, Uta, additional, Fischer, Lutz, additional, Dierckx, Rudi A J O, additional, Hartog, Hermien, additional, and Bokkers, Reinoud P H, additional

Published
2024
Full Text
View/download PDF

7. Marklald: Plasma biomarkers as key indicators for monitoring patients with lysosomal acid lipase deficiency treated with sebelipase alfa. Preliminary findings from a multicentre cohort study in Spain

Author

Roca-Esteve, Sonia, Gonzalo, Irene Serrano, Montero, Javier Adolfo De Las Heras, Bernabeu, Jesus Quintero, Mercadal-Hally, Maria, Almohalla, Carolina, Balmaseda, Elena, Blasco-Alonso, Javier, Martínez, Marta Casañas, Lopez, Maria Jose De Castro, Madurga, Laura Escartín, Gutiérrez Carrasquilla, Liliana P., Berto, Tomas Hernández, Ibarretxe, Daiana, Blázquez, Cristina Iglesias, Martinez-Triguero, Maria Luisa, Mohand, Patricia Pérez, Gil, Nuria P., Ramos, Andrea S., Yahyaoui, Raquel, de Frutos, Laura López, Giraldo, Pilar, and Cebolla, Jorge J.

Published
2025
Full Text
View/download PDF

10. Diagnostic action against hypertransaminasemia in paediatrics: Consensus document of Sociedad Española de Gastroenterología, Hepatología y Nutrición Pediátrica (SEGHNP), Asociación Española de Pediatría de Atención Primaria (AEPap) and Sociedad Española de Pediatría de Atención Primaria (SEPEAP)

Author

Ros Arnal, Ignacio, Reyes Andrade, Joaquín, Mercadal Hally, María, Blesa Baviera, Luis Carlos, García Tirado, Diana, Campuzano Martín, Samuel Héctor, de la Calle Navarro, Estela, and Vegas Álvarez, Ana María

Published
2022
Full Text
View/download PDF

11. Actuación diagnóstica ante hipertransaminasemia en pediatría: documento de consenso de Sociedad Española de Gastroenterología, Hepatología y Nutrición Pediátrica (SEGHNP), Asociación Española de Pediatría de Atención Primaria (AEPap) y Sociedad Española de Pediatría de Atención Primaria (SEPEAP)

Author

Ros Arnal, Ignacio, Reyes Andrade, Joaquín, Mercadal Hally, María, Blesa Baviera, Luis Carlos, García Tirado, Diana, Campuzano Martín, Samuel Héctor, de la Calle Navarro, Estela, and Vegas Álvarez, Ana María

Published
2022
Full Text
View/download PDF

14. Epstein–Barr virus‐associated risk factors for post‐transplant lymphoproliferative disease in pediatric liver transplant recipients

Author

Quintero Bernabeu, Jesus, primary, Juamperez, Javier, additional, Mercadal‐Hally, Maria, additional, Larrarte King, Mauricio, additional, Gallego Melcon, Soledad, additional, Gros Subias, Luis, additional, Sábado Álvarez, Constantino, additional, Soler‐Palacin, Pere, additional, Melendo Pérez, Susana, additional, Esperalba, Juliana, additional, Navarro Jiménez, Alexandra, additional, Garrido Pontnou, Marta, additional, Camacho Soriano, Jessica, additional, Hidalgo Llompart, Ernest, additional, Bilbao Aguirre, Itxarone, additional, and Charco Torra, Ramón, additional

Published
2022
Full Text
View/download PDF

18. Successful Treatment with Rituximab and Immunoadsorption for an Auto-Antibody Induced Bile Salt Export Pump Deficiency in a Liver Transplanted Patient

Author

Quintero, Jesús, Juamperez, Javier, Gonzales, Emmanuel, Julio, Ecaterina, Mercadal-Hally, Maria, Collado-Hilly, Mauricette, Marín-Sánchez, Ana, Charco, Ramon, and Universitat Autònoma de Barcelona

Subjects
medicine.medical_specialty, medicine.medical_treatment, Case Report, Liver transplantation, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Cholestasis, 030225 pediatrics, Internal medicine, medicine, Cholestasis, progressive familial intrahepatic 2, Immunoadsorption, Child, Hepatology, medicine.diagnostic_test, business.industry, Progressive familial intrahepatic cholestasis, medicine.disease, Bile Salt Export Pump, Liver biopsy, Pediatrics, Perinatology and Child Health, 030211 gastroenterology & hepatology, Rituximab, Complication, business, medicine.drug
Abstract

We present an 8 years old girl who was diagnosed at 6 months of age of Progressive Familial Intrahepatic Cholestasis type 2. Although liver transplantation (LT) was classically considered curative for these patients, cholestasis recurrence with normal gamma-glutamyl transpeptidase (GGT), mediated by anti-bile salt export pump (BSEP) antibodies after LT (auto-antibody Induced BSEP Deficiency, AIBD) has been recently reported. Our patient underwent LT at 14 months. During her evolution, patient presented three episodes of acute rejection. Seven years after the LT, the patient presented pruritus with cholestasis and elevation of liver enzymes with persistent normal GGT. Liver biopsy showed intrahepatic cholestasis and giant-cell transformation with very low BSEP activity. Auto-antibodies against BSEP were detected therefore an AIBD was diagnosed. She was treated with Rituximab and immunoadsorption with resolution of the AIBD. As a complication of the treatment she developed a pneumocystis infection successfully treated with corticoids, cotrimoxazol and anidulafungin.

Published
2020

19. Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents

Author

Quintero, Jesús., Juampérez, Javier, Julio, Ecaterina, Cabello, Vanessa, Mercadal-Hally, Maria, Soler-Palacín, Pere, Segarra, Óscar., Rodrigo Gonzalo de Líria, Carlos, and Universitat Autònoma de Barcelona

Abstract

Introduction: Hepatitis C virus infection is world health problem. The aim of this study was to assess the safety and efficacy of ledipasvir/sofosbuvir combination in chronic Hepatitis C Virus (HCV) genotype 1 and 4 infection in paediatric patients. Methods: Eligible patients to be treated with ledipasvir/sofosbuvir were patients from 6 to 18 years old with a chronic HCV genotype 1 or 4 infection. The duration and doses of antiviral drugs were changed depending on patient age, fibrosis stage, and PEGylated interferon + ribavirin experience status. The primary efficacy endpoint was the percentage of patients with a sustained virological response 12 weeks post-treatment. Results: A total of nine patients (7 males) with a median age of 14.8 years (8.48-17.91) were treated with ledipasvir/sofosbuvir combination. Five patients received previous treatment with PEGylated interferon + ribavirin during a median of 8.5 months (3-12 months). Eight patients had some degree of fibrosis (1 patient presented with F1, three patients F2, 2 patients F3, and 2 patients F4). The median pre-treatment viral load was 6.2 Log [5.9-6.8] with the HCV RNA becoming negative six weeks after starting the treatment in 100% of the patients. All patients maintained a sustained viral response at 12 weeks. Three patients (33.3%) had some type of adverse effect (2 headache and one oral thrush). The median post-treatment follow-up was 24 weeks (12-104). Conclusions: Treatment with ledipasvir/sofosbuvir in paediatric patients with chronic HCV infection genotype 1 and 4 is safe and effective with SVR12 and similar to those reported in adults.

Published
2019

20. Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents Combinación de ledipasvir/sofosbuvir como tratamiento de la infección crónica por hepatitis C

Author

Quintero, Jesús., Juampérez, Javier, Julio, Ecaterina, Cabello, Vanessa, Mercadal-Hally, Maria, Soler-Palacín, Pere, Segarra, Óscar., Rodrigo Gonzalo de Líria, Carlos, and Universitat Autònoma de Barcelona

Abstract

Introduction: Hepatitis C virus infection is world health problem. The aim of this study was to assess the safety and efficacy of ledipasvir/sofosbuvir combination in chronic Hepatitis C Virus (HCV) genotype 1 and 4 infection in paediatric patients. Methods: Eligible patients to be treated with ledipasvir/sofosbuvir were patients from 6 to 18 years old with a chronic HCV genotype 1 or 4 infection. The duration and doses of antiviral drugs were changed depending on patient age, fibrosis stage, and PEGylated interferon + ribavirin experience status. The primary efficacy endpoint was the percentage of patients with a sustained virological response 12 weeks post-treatment. Results: A total of nine patients (7 males) with a median age of 14.8 years (8.48-17.91) were treated with ledipasvir/sofosbuvir combination. Five patients received previous treatment with PEGylated interferon + ribavirin during a median of 8.5 months (3-12 months). Eight patients had some degree of fibrosis (1 patient presented with F1, three patients F2, 2 patients F3, and 2 patients F4). The median pre-treatment viral load was 6.2 Log [5.9-6.8] with the HCV RNA becoming negative six weeks after starting the treatment in 100% of the patients. All patients maintained a sustained viral response at 12 weeks. Three patients (33.3%) had some type of adverse effect (2 headache and one oral thrush). The median post-treatment follow-up was 24 weeks (12-104). Conclusions: Treatment with ledipasvir/sofosbuvir in paediatric patients with chronic HCV infection genotype 1 and 4 is safe and effective with SVR12 and similar to those reported in adults.

Published
2019

22. Asociaciones de probióticos para la prevención de la enterocolitis necrosante y la reducción de la sepsis tardía y la mortalidad neonatal en recién nacidos pretérmino de menos de 1.500g: una revisión sistemática

Author

Baucells, Benjamin James, Mercadal Hally, Maria, Álvarez Sánchez, Airam Tenesor, and Figueras Aloy, Josep

Abstract

Los recién nacidos pretérmino y de muy bajo peso presentan mayor riesgo de enterocolitis necrosante (ENC) dado que su colonización a nivel intestinal se produce más tardíamente y es diferente respecto de los recién nacidos a término, además de presentar con mayor frecuencia otros factores favorecedores como isquemia intestinal. Se cree que los probióticos pueden modificar la microbiota y la respuesta inmunitaria de los recién nacidos, disminuyendo la incidencia de ENC.

Published
2016
Full Text
View/download PDF

23. Infectious complications of non-surgical biliary tract manipulation in paediatric patients. Role of antibiotic prophylaxis

Author

Soria-Navarro, Beatriz, Mendoza-Palomar, Natalia, Juampérez-Gomi, Javier, Melendo, Susana, Mercadal-Hally, Maria, Lung, Mayli, Pérez, María Mercedes, Quintero, Jesús, and Soler-Palacin, Pere

Abstract

Infections related to non-surgical manipulation of the biliary tract (NSMBT) are common events despite periprocedural antibiotic prophylaxis (PAP). Since June 2017, our local protocol has indicated a 24-h regimen of intravenous piperacillin–tazobactam for this purpose.

Published
2021
Full Text
View/download PDF

24. Less is more: The use of single biodegradable stenting to treat biliary anastomotic strictures in pediatric liver transplantation.

Author

Quintero Bernabeu J, Juamperez Goñi J, Mercadal Hally M, Padrós Fornieles C, Larrarte King M, Molino Gahete JA, Coma Muñoz A, Diez Miranda I, Pérez Lafuente M, Charco Torra R, and Hidalgo Llompart E

Abstract

This study reports our experience of using biodegradable biliary stents (BBSs) for anastomotic biliary strictures (ABSs) in pediatric patients undergoing liver transplants. It involves the analysis of a retrospective data collection from January 2014 to January 2023, including all pediatric recipients of liver transplants in our center treated for ABSs with BBSs. In phase 1 (2014-2019), there was an initial percutaneous transhepatic cholangiography with anastomotic dilatation followed 2 weeks after a second percutaneous transhepatic cholangiography with BBS insertion. In phase 2 (2019-2023), the BBS was placed shortly after ABS dilatation, requiring only 1 percutaneous transhepatic cholangiography. All patients were followed up with routine tests and ultrasound. Forty-six ABSs were diagnosed in 43 pediatric recipients of liver transplants with a median of 6.7 months after liver transplantation (0.1-246.8 mo). Eight out of 46 ABSs (17.4%) treated with BBSs relapsed (median recurrence time: 6.5 mo; 1.6-17.0 mo). Four resolved with further BBS placement; only 4 needed surgical revision (8.7%) after a median follow-up time of 43.9 months (0.3-106.3). There were no differences in ABS recurrence rate, time between stent placement and recurrence, or the presence of cholangitis based on whether the BBS was deployed in 1 or 2 steps. Patients with end-to-end anastomosis had a higher ABS recurrence (OR 10.8; 1.4-81.3, p = 0.008) than those with bilioenteric anastomosis. The use of biodegradable stents could be a good option for treating ABSs in pediatric patients undergoing liver transplants, with our series showing a success rate of over 90% and an average follow-up of 43.9 months., (Copyright © 2024 American Association for the Study of Liver Diseases.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results